Skip to content
Trial Eligibility
Menu

A Study of Romosozumab in People With Breast Cancer and Osteoporosis

NCT07776613

This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

The researchers are doing this study to see if romosozumab is effective at helping with bone formation in people with metastatic breast cancer (MBC) that has spread to the bones. All participants will have osteoporosis. The researchers will also look at bone breakdown (resorption) in participants and determine if romosozumab is a safe treatment for osteoporosis in people with MBC that has spread to the bones.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Breast Cancer
  • Metastatic Breast Cancer (MBC)

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 years and older
Sex
Female
Healthy volunteers
Not accepted
Sponsor
Memorial Sloan Kettering Cancer Center
Last updated on ClinicalTrials.gov
August 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New Jersey · 3

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, NJ

New York · 4

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) · Commack, NY
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, NY
  • Memorial Sloan Kettering Cancer Center · New York, NY
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) · Uniondale, NY

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.